Health Check: On Garfield the Cat Day, the biotech sector purrs with deals and breakthroughs
Singular Health inks US physician network deal
Clarity clearly is undervalued, say brokers
Among other auspicious events, the 19th of June marks the end of slavery in the US, Garfield the Cat Day and the birthdays of former British PM Boris Johnson and royal temptress Wallis Simpson.
So why not add a slew of meaningful life sciences announcements, including an HIV vaccine breakthrough, to the June 19 pantheon?
Let's start with Orthocell (ASX:OCC), which reports 'compelling data' showing its Remplir nerve repair agent is superior to suture-only standard techniques.
Stitching accounts for circa 90% of the 700,000 nerve repair procedures done in the US annually.
A cuff that envelops the damaged peripheral nerves, Remplir reduces the use of stitching, which can compromise nerve repair.
Orthocell's study used a rat sciatic nerve injury model, covering 48 rodents across four treatment groups.
These cohorts covered repairs using one, three or six sutures, compared with one suture augmented with Remplir.
The rats' nerve function and regeneration were evaluated up to 12 weeks post-treatment.
The FDA ticked off Remplir in early April and the device is also approved in Canada, Hong Kong, Singapore, New Zealand and here.
Thus, the study was pitched not so much as approval as supporting the US sales rollout.
Orthocell cites a total addressable market in its target markets of US$3.5 billion, with its already-approved geographies accounting for US$1.8 billion.
The US market is worth US$1.6 billion.
Stem-cell hope for bone marrow transplant patients
NeuroScientific Biopharmaceuticals (ASX:NSB) highlights previous clinical data showing its soon-to-be acquired stem cell platform is effective in preventing graft-versus-host disease (GvHD).
The company is buying the asset, Stemsmart from the unlisted Perth-based Isopogen.
The phase I work covered adults and children with life-threatening, steroid-resistant GvHD, a common complication of bone-marrow transplants.
The data shows the treatment is safe and well tolerated, 'with no infusion related toxicities'.
Furthermore, most adults and children had a 'complete or partial resolution of symptoms and improved survival'.
Of the 10 children treated on compassionate grounds, all had survived 12 months post implant. Three of them were still alive six years post treatment.
Turning to pancreatic cancer, Amplia (ASX:ATX) reports another patient with a 'complete response' in its 55-patient trial dubbed Accent.
As close as dammit to a cure, a confirmed complete response formally is defined as all tumour lesions disappearing, with the effect maintained for at least two months.
'This is a rare outcome in advanced pancreatic cancer where the disease has spread to other parts of the body,' the company says.
A Singularly fine US deal
Imaging medtech outfit Singular Health Group Ltd (ASX:SHG) has signed a $2 million agreement with a US physician network to develop and use Singular's 3Dicom medical imaging tool.
The compact is with Provider Network Solutions (PNS), covering physician networks in Puerto Rico, Florida, and Texas.
It covers the initial deployment of 1000 3Dicom licences, at US$800 each.
Singular pockets a further US$500,000 on 'satisfaction of AI model marketplace and image repository development and integration'.
The company hope to expand to the remaining 30 states that PNS covers.
3Dicom converts magnetic resonance imaging and computed tomography scans to enable 'immersive visualisation' with three-dimensional images.
Singular also said it had received $8 million of firm commitments in its recently-announced placement.
Meanwhile, microbiome testing house Microba Life Sciences (ASX:MAP) is on trading halt pending a capital raising.
EZZ girds for US launch
Hitherto China and locally focused, health supplements outfit EZZ Life Science (ASX:EZZ) has launched four initial products into the US after winning FDA approval.
To be sold under the new Ezzday banner, the products are made in the US and are tailor-made for American consumers.
Seeing you asked, the remedies cover de-bloating/de-gassing, vaginal probiotics, skincare and colon detox. Readers can draw their own conclusions as to what that means about the State of the Nation in Trumpian times.
Initially, the products will be sold via Amazon and Shopify.
Locally EZZ sells via more than 600 chemists and globally via 750 ecommerce platforms, including China's Douyin and Tmall.
The company values the US supplements market at US$100 billion a year, pipping China's US$80 billion opportunity.
US health secretary Robert F Kennedy Junior (RFK Jr) has a special interest in health supplements, which at the very least shouldn't harm EZZ's US ambitions.
EZZ shares have been on a tear – up 33% over the last month – but they are still well shy of the record $5 peak in October last year.
HIV jab spells hope for end to '45-year pandemic'
Speaking of RFK Jr, the FDA has approved a drug that is meant to protect against HIV with a single administration every six months.
Yep – it's a vaccine – so maybe the health czar isn't as avowedly anti-vaxx as we all think.
Marketed as Yeztugo by Gilead Sciences, lenacapavir is seen as the best hope of knocking HIV – in effect a 45-year pandemic – on its head.
Clinicians say the drug is much more powerful than the current oral treatments and almost 100% effective.
'This is a historic day in the decades-long fight against HIV,' Gilead CEO Daniel O'Day said.
'Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic.'
The drug has a list price of US$28,218 ($43,300). But Gilead may provide the vaccine free to non-insured patients.
Have investors underestimated Clarity?
Is radiopharmacy outfit Clarity Pharmaceuticals (ASX:CU6) a case of 'objects in this rear view mirror are closer than you think'?
Following a series of clinical updates from Clarity, broker Canaccord values the company at $6.74 a share, a lofty 210% increment on the current price.
In March, Wilsons ascribed an even ballsier $8.25 a share.
All things being equal – and they never are – that would value Clarity at $2.6 billion.
Sector champ Telix Pharmaceuticals (ASX:TLX) is worth around $8 billion, bearing in mind it has two FDA-approved prostate cancer imaging tools and a kidney cancer consent in the offing.
Yesterday, Clarity said it has struck an agreement with US mob Spectronrx.
Spectronrx will provide 400,000 patient-ready does of its copper isotope based 64Cu-SAR-bisPSMA (for diagnosing and potentially treating prostate cancer).
In the nuclear medicine game, gaining access to nearby doses is half the battle. But this agent's generous half-life means it can be distributed across all 50 US states.
Clarity recently announced promising phase II results for 64Cu-Sartate (neuroblastoma) and 64Cu-SAR-Bombesin (PSMA-negative prostate cancer).
Another program, Secure, focuses on identifying and treating metastatic castration-resistant prostate cancer.
Clarity currently has no approved products, but Canaccord expects 64Cu-SAR-bisPSMA to be on market by mid 2027.
'Recent commercial agreements should remind the market that this potential best-in-class asset could be closer than we think.'
The firm reckons Clarity can win a 20% share of the US market, for US$520m in peak sales.
Your columnist's nuclear science credentials – the ones plucked from a Weeties pack – are out of date.
But it looks like Telix should have one eye on the rear-view mirror and the other on the road ahead.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
2 hours ago
- News.com.au
Eye-watering sum rare ceratosaur fossil sold for at auction
A rare Ceratosaurus fossil, one of only four known to exist, has sold at $46.5 million at a Sotheby's auction. Described in a statement by the auction house as 'one of the finest and most complete examples of its kind ever found,' it vastly surpassed the estimated value, which was listed last month at $6 million to $9 million. The dinosaur fossil was discovered in 1996 on privately owned land in Albany County, Wyoming, in Bone Cabin Quarry, an area known to be a rich source of fossils due to its location in the Morrison Formation, a rock unit from the Late Jurassic Period. The carnivorous predator is a theropod, a term classed for a diverse group of dinosaurs characterised by thin-walled bones and the ability to stand and run on their two hind limbs. The Ceratosaurus weighed up to two tons, and was easily distinguished by its nasal crest, elongate teeth, and a row of sharp bones running down the middle of its back and tail. It also featured a fourth clawed finger, which differed from its three-clawed theropod peers. While the $46.5 million price tag may seem steep, it's far from the first of its kind. Last year, Sotheby's made history with the stegosaurus fossil 'Apex', which fetched $68 million, nine times more than the presale estimate. In 2020, a Tyrannosaurus rex fossil, popularly known as 'Stan', was sold by auction house Christie's for $48 million. Mark Westgarth, an Associate Professor in Art History & Museum Studies at the University of Leeds, told CNN that the successful sale falls in line with the recent revival of interest in fossils and natural history. 'At the top end of the market … seems to be about an increasing desire for 'distinction,'' said Westgarth. 'These dinosaur specimens also have a particular aesthetic — they are sculptural and awe-inspiring.' There were six hopeful bidders competing for the Ceratosaurus, both online and over the phone. Cassandra Hatton, Vice Chairman and Global Head of Science and Natural History at Sotheby's said that there was an upturn in the number of people who registered to participate in the auction. 'I've had so many people who'd started off in this market who completely stopped because they'd been burned,' Ms. Hatton told the New York Times. 'A lot of those people who were excited years ago and got turned off are coming back.' The specimen, which is the only juvenile of its kind, has not been studied or described formally in publication, Sotheby's revealed. While the identity of the winning bidder has not been revealed, Ms Hatton has shared that the buyer intends to loan the specimen to a museum.
News.com.au
4 hours ago
- News.com.au
Australian passport losing its power compared to many other nations
Australia has fallen from sixth to seventh place in the latest Henley Passport Index, trailing countries such as Singapore, New Zealand and the UK. The Henley Passport Index ranks passports according to the number of places travellers can enter without a visa or with visa-on-arrival access. Australia now shares seventh place with Czechia, Hungary, Malta and Poland. Singapore is the world's most powerful passport, with visa-free access to 193 destinations out of 227. Japan and South Korea are in equal second place, each giving citizens access to 190 destinations visa-free. Seven countries are in third place including France, Germany, Ireland and Italy. They have access to 189 destinations. In fourth place there are also seven countries including Belgium, Sweden, Norway and Portugal. They have visa-free entry to 188 destinations. New Zealand is in fifth spot, along with Switzerland, while the UK is in sixth place. The US has slipped to 10th place and is close to falling out of the top 10 for the first time since the index began almost 20 years ago. Afghanistan remains at the bottom of the list, with its citizens able to access just 25 destinations without a prior visa. Australians are still able to enter many countries without needing a visa beforehand. The data shows a general global shift towards more openness, mobility and passport strength. Over the past decade, more than 80 passports have climbed at least 10 places, and the global average number of destinations travellers can access visa-free has almost doubled from 58 in 2006 to 109 in 2025. Notably, China has climbed 34 places from 94th to 60th since 2015. China has granted visa-free access to more than a dozen new passports since January, bringing its total to 75. These include Bahrain, Kuwait, Oman and Saudi Arabia. Henley and Partners chief executive Juerg Steffen said Americans were leading the demand worldwide for alternative residence and citizenship options, with British nationals also among the top five. 'As the US and UK adopt increasingly inward-looking policies, we're witnessing a marked rise in interest from their citizens seeking greater global access and security,' he said. 'Your passport is no longer just a travel document – it's a reflection of your country's diplomatic influence and international relationships.
ABC News
10 hours ago
- ABC News
As West Coast prepares monster Harley Reid offer, it is time for the AFL to consider introducing max contract lengths
Over 25 years ago, the NBA decided enough was enough and flexed a key cap mechanism, introducing maximum contract lengths. The 90s had seen teams dish out ridiculously long contracts, ones that had the potential to handicap them for the best part of a decade. One of the more notorious examples saw Juwan Howard, the fifth overall pick in the 1994 draft, locked into a 12-year, $42 million deal with the Washington Bullets, one which gave him an option to opt out after two years. The NBA's current rules mean the longest contract that a player can now earn is a five-year deal with their own team, or a four-year deal if they sign with a rival. It is a mechanism that essentially protects teams from themselves, even if it limits the amount of financial security for the players. Even with this measure, NBA teams still make bad signings and players have bad contracts, but at least the length of the financial damage to a team's cap sheet is limited. With lengthy extensions becoming more and more popular over the last few years, the AFL, too, has started to save teams from their own mishaps, and would be well served to do more in coming years. Since the start of the 2024 season, AFL teams offering contracts longer than six years must submit written approval from their president and CEO, explaining the deal. It is like trying to convince your parents why you should buy a brand-new PS5. That move came after Brodie Grundy, now with Sydney, was moved twice by two different clubs, Collingwood and Melbourne, in the space of two years. The seven-year extension Grundy signed runs through 2027. By the time it expires, he will have played for at least three different clubs over the duration of the contract. No one was to blame for the Grundy extension in hindsight. His management was well within its rights to ask for top dollar from the Magpies, given he was a two-time All-Australian and one of the best big men in the game at the time. The decision was simple for Collingwood: either pay Grundy or lose him to a rival club, leaving a gaping hole at the ruck position. A couple of teams in the AFL currently face the same conundrum the Magpies did at the end of 2019, namely West Coast, which is trying to retain the services of their prolific youngster, Harley Reid. The Eagles have won a combined 10 games in four seasons, and currently have an abysmal 1-17 record so far this year. Despite spending four years as the AFL's cellar-dwellers, Reid is the only Eagles player who seems a sure bet to make an All-Australian team in the future, making locking him up a priority for the club. Ever since Eagles selected Reid, a Victorian native, first overall in the 2023 draft, clubs from his home state have been sniffing around the prospect of prying him out of Western Australia. The bidding war has allowed Reid's management to drive up his asking price. The latest number being thrown around is a reported 11-year extension that would net Reid an estimated total of $20 million across the duration of the deal. The AFL hasn't seen numbers like this before, so understandably, there is apprehension around the competition, particularly due to the fact that Reid has played 38 career games and blown hot and cold in those, as you'd expect from a 20-year-old in his second season. From an Eagles perspective, the deal is a no-brainer. You simply pay whatever you can to keep your crown jewel and worry about the rest later. West Coast might not be winning very often, but Reid's presence still draws significant interest, which is of tangible value to the club. The idea of what he might be is enough to keep fans entertained. Rival clubs may not be willing to match the 11 years West Coast is offering, but are clearly prepared to stump up well in excess of $1 million per annum if it means Reid is spending his prime years running around in their guernsey. Like the situation with Grundy and Collingwood, no one is necessarily at fault. This just happens to be the price of doing business. St Kilda finds itself in a similar boat when it comes to the seemingly intertwined futures of Nasiah Waganeen-Milera, who is already at the club, and Tom De Koning, whom the Saints are trying to acquire this summer. The Saints have been big-game hunting for a few years now, and everyone in the league knows it. They failed to lure Finn Callaghan and Essendon captain Zach Merrett to come to the club in the last 12 months, but appear to have turned the head of Carlton's De Koning. De Koning has been reportedly offered a deal in the vicinity of $1.7 million per season to leave the Blues, a deal which has seen Waganeen-Milera's camp raise his asking price to $1.4 million per year amid interest from both South Australian clubs. St Kilda, which is currently flush with salary cap space, can afford to sign both players to huge deals, but will likely restrict itself moving forward by committing such a large portion of its cap to two players. People in power at all these clubs have one thing in common: trying to follow through on whatever the message is to their members. The only thing that differs is what exactly that message is. For West Coast, the message is one of hope, patience, and an idea of what could be. Pitching that to fans is doable when Reid is the centrepiece of it. Good luck doing it while he's ripping it up back in Victoria after being traded by the Eagles. The Saints have an entirely different mandate. This is a club that has not had any real star-power since the Nick Riewoldt era a decade ago. To those in charge at St Kilda, giving the fans a shiny new toy in De Koning makes paying him well above the usual going rate for a ruckman worth it. People in power at each of these clubs are trying to appease their members as quickly as possible. If that means handicapping the club in the long run, a time when they may not still remain at the club in their respective positions, it is a decision they'll make every single time. This isn't a problem that is AFL-exclusive. Across all sports, if you leave clubs to their own vices, the chances are they make short-sighted decisions that usually result in adversely impacting their long-term futures. The AFL cannot make any changes until the end of the current Collective Bargaining Agreement (CBA), which ends in 2027. When it comes to the negotiation of a new deal, contract lengths should be central to these discussions, particularly with expansion on the horizon. The current AFL administration has already shown an inclination to keeping a close eye on how the NBA does things, dabbling in play-in tournament and in-season cup ideas. If there is one thing they can actually take from the NBA, it should be contract lengths.
